(RTTNews) - Novel bioelectric medicine company Pulse Biosciences, Inc. (PLSE) announced Friday the appointment of Paul LaViolette, current Co-Chairman of the Board, as Chief Executive Officer.
Pulse Biosciences targets CE Mark submission in 2026 as nPulse platform advances clinical milestones
CEO Paul LaViolette stated that Pulse Biosciences is “creating a pulsed field ablation platform to completely shift how physicians treat disease” by advancing nanosecond pulsed field ablation (nsPFA), ...
IRVINE, Calif., July 15, 2020 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, ...
On May 11, 2026, Paul A. LaViolette, Chief Executive Officer of Pulse Biosciences (NASDAQ:PLSE), a developer of non-thermal bioelectric treatments, reported the direct purchase of 15,000 shares of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results